Ann Bunnenberg

Welcome to dEEGtal, a startup aiming at revolutionizing the early detection of epilepsy through advanced diagnostic software. Leveraging artificial intelligence to analyze electroencephalogram (EEG) data, our mission is to enhance the accuracy and efficiency of epilepsy diagnoses. Our software-as-a-service (SaaS) platform, currently under development, integrates seamlessly into existing healthcare workflows, providing neurologists the perfect companion to diagnose epilepsy. Follow our journey as we transform epilepsy care with innovation and precision in medical technology.

Drug Discovery, Biotech Services, Lab Animal Services, Custom Synthesis, Animal Models.

WellRithms is boldly transforming the landscape of healthcare reimbursement with a vision for a system that benefits everyone. Our message is simple: healthcare payers deserve a just price, and providers should receive fair reimbursement. As the master of payment integrity, were pioneering a human-first, innovative approach for self-funded group health and workers compensation medical billing. Our data-driven methodology, coupled with medical acumen, ensures precise review and repricing of medical claims. We aim to eradicate errors, counteract abusive billing, and detect potential fraud. Guided by our physician-led team and a shared set of pioneering values, WellRithms stands as a beacon for those seeking to navigate the complexities of healthcare reimbursement. With us by your side, we can jointly champion the mission to curb escalating healthcare expenses. Together, well ensure a more equitable and sustainable healthcare future.

Welcome to dEEGtal, a startup aiming at revolutionizing the early detection of epilepsy through advanced diagnostic software. Leveraging artificial intelligence to analyze electroencephalogram (EEG) data, our mission is to enhance the accuracy and efficiency of epilepsy diagnoses. Our software-as-a-service (SaaS) platform, currently under development, integrates seamlessly into existing healthcare workflows, providing neurologists the perfect companion to diagnose epilepsy. Follow our journey as we transform epilepsy care with innovation and precision in medical technology.

Drug Discovery, Biotech Services, Lab Animal Services, Custom Synthesis, Animal Models.

Founded in 2007, the Oregon Venture Fund is a community supported, professionally managed, collaborative venture capital fund backed by the leaders of the regions business, technology, and entrepreneurial communities. Pitchbook consistently places OVF in the top 25% of all global venture funds (2025). OVF invests $15-20 million annually in the most promising startups and growth companies, regardless of stage or sector, in Oregon and Southern Washington. Learn more about OVF in our quick overview video: https://www.youtube.com/watch?v=jxiH6O4BEp0 Over 6500+ jobs have been created by the 90 companies in the portfolio. Some of OVF’s largest investors include the State of Oregon, Oregon Community Foundation, and Meyer Memorial Trust. In 2023, the group launched Oregon Venture Fund XV, to accommodate additional institutional investors and family offices. The $25M+ fund has a 5-year investing period and invests alongside each annual Oregon Venture Fund in the same portfolio. OVF receives generous support from Tonkon Torp LLP, Geffen Mesher & Co., and Stoel Rives.